Compare GSK plc (GSK) vs Howmet Aerospace Inc (HWM) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

Howmet Aerospace (HWM) trades at $275.54, down 0.45% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats and impressive profitability metrics including 20.22% net income margin and 33.98% ROE. Recent news highlights strength in commercial aerospace demand driving growth prospects.

The outlook remains positive with analyst consensus targeting $317.63 (15% upside) and 84% buy ratings. Key catalysts include Q2 2026 earnings announcement on August 6, 2026, and sustained aerospace demand. Risks include premium valuation multiples and potential market volatility affecting the high-growth trajectory.